The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Fasinex     6-chloro-5-(2,3- dichlorophenoxy)-2...

Synonyms: Egaten, Triclabendazol, Fasinex (TN), BEN631, SureCN165712, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Triclabendazole


High impact information on Triclabendazole

  • Mature Fasciola hepatica of the triclabendazole-resistant Sligo isolate were incubated in vitro with 10 microg/ml of the sulphoxide metabolite of compound alpha [5-chloro-2-methylthio-6-(1-naphthyloxy)-H-benzimidazole]; the metabolite will be referred to as alpha.SO [5].
  • We did not observe a reduction in fitness in the Oberon isolate which has been reported to be triclabendazole-resistant, compared to the triclabendazole-susceptible Fairhurst isolate, but considerable inter- and intra-isolate variability at different life-cycle stages was recorded [6].
  • The clastogenic effects of fasinex were tested in lymphocyte cultures of the river buffalo at three final concentrations: 25, 50 and 100 microg/ml [7].
  • Immunocytochemical studies, using an anti-tubulin antibody, showed that tubulin organization was disrupted in the tegument of triclabendazole-susceptible flukes [8].
  • Sequencing of beta-tubulin cDNAs from triclabendazole-susceptible and triclabendazole-resistant flukes revealed no amino acid differences between their respective primary amino acid sequences [8].

Chemical compound and disease context of Triclabendazole


Biological context of Triclabendazole


Anatomical context of Triclabendazole


Associations of Triclabendazole with other chemical compounds


Gene context of Triclabendazole


Analytical, diagnostic and therapeutic context of Triclabendazole


  1. Single treatment of invasive fascioliasis with triclabendazole. Loutan, L., Bouvier, M., Rojanawisut, B., Stalder, H., Rouan, M.C., Buescher, G., Poltera, A.A. Lancet (1989) [Pubmed]
  2. Treatment of human chronic fascioliasis with triclabendazole: drug efficacy and serologic response. Apt, W., Aguilera, X., Vega, F., Miranda, C., Zulantay, I., Perez, C., Gabor, M., Apt, P. Am. J. Trop. Med. Hyg. (1995) [Pubmed]
  3. Effect of food on the bioavailability of triclabendazole in patients with fascioliasis. Lecaillon, J.B., Godbillon, J., Campestrini, J., Naquira, C., Miranda, L., Pacheco, R., Mull, R., Poltera, A.A. British journal of clinical pharmacology. (1998) [Pubmed]
  4. Efficacy of triclabendazole against fascioloidiasis (Fascioloides magna) in naturally infected white-tailed deer (Odocoileus virginianus). Qureshi, T., Craig, T.M., Drawe, D.L., Davis, D.S. J. Wildl. Dis. (1989) [Pubmed]
  5. Adult triclabendazole-resistant Fasciola hepatica: surface and subsurface tegumental responses to in vitro treatment with the sulphoxide metabolite of the experimental fasciolicide compound alpha. McConville, M., Brennan, G.P., McCoy, M., Castillo, R., Hernandez-Campos, A., Ibarra, F., Fairweather, I. Parasitology (2006) [Pubmed]
  6. Stage-specific differences in fecundity over the life-cycle of two characterized isolates of the liver fluke, Fasciola hepatica. Walker, S.M., Hoey, E., Fletcher, H., Brennan, G., Fairweather, I., Trudgett, A. Parasitology (2006) [Pubmed]
  7. Clastogenic effects of the fasciolicide drug fasinex on river buffalo lymphocyte cultures in vitro. Ahmed, S., Othman, O.E. Mutat. Res. (2003) [Pubmed]
  8. Triclabendazole-resistant Fasciola hepatica: beta-tubulin and response to in vitro treatment with triclabendazole. Robinson, M.W., Trudgett, A., Hoey, E.M., Fairweather, I. Parasitology (2002) [Pubmed]
  9. Comparative studies on the effect of bithionol, praziquantel and triclabendazole in rabbit's fascioliasis. el-Bahy, M.M. Journal of the Egyptian Society of Parasitology. (1997) [Pubmed]
  10. Antioxidant capacity in Fasciola hepatica patients before and after treatment with triclabendazole alone or in combination with ascorbic acid (vitamin C) and tocofersolan (vitamin E). Rehim, W.M., Sharaf, I.A., Hishmat, M., el-Toukhy, M.A., Rawash, N.A., Fouad, H.N. Arzneimittel-Forschung. (2003) [Pubmed]
  11. Efficacy and pharmacokinetics of triclabendazole in buffalo with induced fasciolosis. Sanyal, P.K., Gupta, S.C. Vet. Parasitol. (1996) [Pubmed]
  12. Triclabendazole treatment in experimental goat fasciolosis: anthelmintic efficacy and influence in antibody response and pathophysiology of the disease. Martínez-Moreno, A., Jiménez, V., Martínez-Cruz, M.S., Martínez-Moreno, F.J., Becerra, C., Hernández, S. Vet. Parasitol. (1997) [Pubmed]
  13. Triclabendazole biotransformation and comparative diffusion of the parent drug and its oxidized metabolites into Fasciola hepatica. Mottier, L., Virkel, G., Solana, H., Alvarez, L., Salles, J., Lanusse, C. Xenobiotica (2004) [Pubmed]
  14. Uncoupling of rat liver mitochondrial oxidative phosphorylation by the fasciolicide triclabendazole and its sulfoxide and sulfone metabolites. Carr, A.W., McCracken, R.O., Stillwell, W.H. J. Parasitol. (1993) [Pubmed]
  15. Pathological and immunohistochemical study of the liver and hepatic lymph nodes of sheep chronically reinfected with Fasciola hepatica, with or without triclabendazole treatment. Pérez, J., Ortega, J., Moreno, T., Morrondo, P., López-Sández, C., Martínez-Moreno, A. J. Comp. Pathol. (2002) [Pubmed]
  16. Treatment of human pulmonary paragonimiasis with triclabendazole: clinical tolerance and drug efficacy. Calvopiña, M., Guderian, R.H., Paredes, W., Chico, M., Cooper, P.J. Trans. R. Soc. Trop. Med. Hyg. (1998) [Pubmed]
  17. Fascioliasis: sonographic abnormalities of the biliary tract and evolution after treatment with triclabendazole. Richter, J., Freise, S., Mull, R., Millán, J.C. Trop. Med. Int. Health (1999) [Pubmed]
  18. Fasciola hepatica: disruption of the vitelline cells in vitro by the sulphoxide metabolite of triclabendazole. Stitt, A.W., Fairweather, I. Parasitol. Res. (1996) [Pubmed]
  19. The effect of the microtubule inhibitor tubulozole-C on the tegument of triclabendazole-susceptible and triclabendazole-resistant Fasciola hepatica. Robinson, M.W., Trudgett, A., Hoey, E.M., Fairweather, I. Parasitol. Res. (2003) [Pubmed]
  20. Simultaneous determination of triclabendazole and its sulphoxide and sulphone metabolites in bovine milk by high-performance liquid chromatography. Takeba, K., Fujinuma, K., Sakamoto, M., Miyazaki, T., Oka, H., Itoh, Y., Nakazawa, H. Journal of chromatography. A. (2000) [Pubmed]
  21. Treatment of immature and mature Fasciola hepatica infections in sheep with triclabendazole. Boray, J.C., Crowfoot, P.D., Strong, M.B., Allison, J.R., Schellenbaum, M., Von Orelli, M., Sarasin, G. Vet. Rec. (1983) [Pubmed]
  22. Resistance of Fasciola hepatica to triclabendazole and albendazole in sheep in Spain. Alvarez-Sánchez, M.A., Mainar-Jaime, R.C., Pérez-García, J., Rojo-Vázquez, F.A. Vet. Rec. (2006) [Pubmed]
  23. Activity of closantel against adult triclabendazole-resistant Fasciola hepatica. Coles, G.C., Rhodes, A.C., Stafford, K.A. Vet. Rec. (2000) [Pubmed]
  24. IL-1, IL-4 production and IgE levels in acute and chronic fasciolosis before and after triclabendazole treatment. Allam, A.F., Osman, M.M., el-Sayed, M.H., Demian, S.R. Journal of the Egyptian Society of Parasitology. (2000) [Pubmed]
  25. An outbreak of subacute fasciolosis in Soay sheep: ultrasonographic biochemical and histological studies. Scott, P.R., Sargison, N.D., Macrae, A., Rhind, S.R. Vet. J. (2005) [Pubmed]
  26. Assay of triclabendazole and its main metabolites in plasma by high-performance liquid chromatography. Alvinerie, M., Galtier, P. J. Chromatogr. (1986) [Pubmed]
  27. Isolation, identification and expression of a Fasciola hepatica cDNA encoding a 2.9-kDa recombinant protein for the diagnosis of ovine fasciolosis. Paz-Silva, A., Hillyer, G.V., Sánchez-Andrade, R., Rodríguez-Medina, J.R., Arias, M., Morrondo, P., Díez-Baños, P. Parasitol. Res. (2005) [Pubmed]
WikiGenes - Universities